'The worldwide market for regenerative medicine is conservatively estimated to be $500 billion by 2010'

Overview

HEALTHeUNIVERSE Inc. is a biotechnology development firm specializing in the development and commercialization of patented Biopharmaceutical and Biomedical products. The Company is engaged in research and development of regenerative medicine therapies using non-embryonic adult stem cells for use in plastic, reconstructive, orthopedic, vascular, and cardiac surgery. Healtheuniverse strives to be the first to commercialize the use of regenerative medicine in plastic and reconstructive surgery and to develop therapeutic uses in the most profitable commercial applications.
 

Investment Highlights

Profile

Regenerative medicine is the vanguard of 21st century healthcare. The company is on the cusp of a worldwide explosion of activity in this rapidly growing field of biomedicine that will revolutionize health care treatment. Regenerative medicine will lead to the creation of fully biological or bio-hybrid tissues and organs that can replace or regenerate tissues and organs damaged by disease, injury, or congenital anomaly. Because of the economic potential of this industry (the worldwide market for regenerative medicine is conservatively estimated to be $500 billion by 2010), initiatives to capture significant market share are multiplying around the world.
 

Healtheuniverse specializes and is currently striving to be the first to commercialize the use of non-embryonic stem cell therapy applications in the field of Plastic, Reconstructive and Cosmetic Surgery. The market for plastic, reconstructive, and cosmetic surgery procedures today exceeds $15 billion per year. It's estimated that cosmetic surgery procedures represent approximately $10 billion of industry revenues. Plastic Surgery encompasses both reconstructive and aesthetic surgery, commonly referred to as cosmetic surgery. While not essential to physical health, aesthetic surgery can improve the appearance of normal body features and enhance self image and is the most promising sector for profit driven use of regenerative medicine and stem cell applications.
 

Healtheuniverse is locating substantially all research and development operations in Biopolis Singapore to take advantage of its world-class R&D environment, state-of-the art facilities, and the availability of shared facilities and services. The Company intends to cut R&D costs significantly while accelerating their development and commercialization timeline. By co-locating with the public research institutes onsite the company feels that it will provide economies of scale to optimize the use of high end resources such as X-ray crystallography, nuclear magnetic resonance, electron microscopy, DNA sequencing and other necessary equipment without incurring the expense and time needed to purchase this equipment.
 

Healtheuniverse believes that regenerative medicine has the potential to revolutionize medicine by being able to produce human cells of any kind for use in a wide-array of surgical and therapeutic applications. The company owns 2 patents and patent applications related to the field of stem cell therapy, which allows the production of stem cells genetically matched to the patient. The Company is focused on being the first to commercialize the use of regenerative medicine in plastic and reconstructive surgery and to develop therapeutic uses in the most profitable commercial applications.
 

Commercial Applications

The company believes that, if successfully developed, stem cell-based therapy has the potential to provide treatment for plastic and reconstructive surgery and a broad range of acute and chronic degenerative diseases. The company also believes the potential applications of cell-based therapeutics include: fat tissue for plastic, reconstructive and cosmetic surgery, myocardial and endothelial vascular tissue for cardiovascular disease, skin cells for dermatological conditions, neural cells for spinal cord injury and other neuro-degenerative diseases, pancreatic cells for diabetes, cartilage cells for arthritis and orthopedic applications.

Specific U.S. Target Markets for Commercialization

Plastic, Reconstructive and Cosmetic Surgery: The market for plastic, reconstructive, and cosmetic surgery procedures today exceeds $15 billion per year. It's estimated that cosmetic surgery procedures represent approximately $10 billion of industry revenues. Plastic Surgery encompasses both reconstructive and aesthetic surgery, commonly referred to as cosmetic surgery. While not essential to physical health, aesthetic surgery can improve the appearance of normal body features and enhance self image.
 

Dermatology: The worldwide market for prescription dermatological drugs is expected to expand at a healthy pace to surpass $10 billion by 2006. The most dynamic segment going forward appears to be the anti-aging segment, where botulinum agents, namely Botox, will change the competitive landscape, according to the study. An aging population, a growing consumerism in prescription markets, and a general trend toward so-called 'lifestyle' drugs point to great success for new products in the anti-aging segment.
 

Orthopedic Surgery: Orthopedic applications and the financial statistics in the US and abroad are huge in terms of both procedures and dollars, and the aging population throughout the developed world will only push those numbers higher. Care for arthritis alone costs well over $100 billion per year worldwide. Musculoskeletal drug sales are estimated at over $15 billion worldwide and have been the fastest growing drug segment in recent years. Orthopedic care represents 10% of all healthcare expenditures, including hospital admissions, and 40% of all emergency room visits. Arthritis and orthopedic impairments, when added together, are the most prevalent chronic conditions in the United States, exceeding sinusitis and allergies, high blood pressure and heart disease, and asthma and chronic bronchitis.
 

Vascular Surgery: Vascular surgery involves diseases and disorders of the peripheral arteries, veins and lymphatic system which commonly include aortic aneurysms and peripheral arterial disease. The cardiovascular and peripheral vascular medicine is a $1.3 billion market in the US.
 

Cardiac Surgery: An aging baby boomer population at increased risk for coronary artery disease (CAD) is driving US demand for less invasive techniques to treat adverse cardiovascular conditions. Rising procedure volumes in the US have made interventional cardiology (IC), the minimally invasive medical specialty concerned with the treatment of CAD, a burgeoning and lucrative market. According to a new report published by Millennium Research Group (MRG), over 1 million Americans underwent a percutaneous coronary intervention (PCI) procedure in 2004, contributing partly to IC market revenue in excess of $4 billion.
 

Wound Care: Wound care is currently estimated to be a $100 Billion market in the US and growing almost exponentially as the Baby Boomer generation age. Recent evidence suggests that coetaneous repair also involves recruitment of non-resident, undifferentiated cells from distant sources, such as fat cells. Populations of progenitor cells have been identified as valuable sources of uncommitted cells that are capable of reconstituting multiple cell types in various tissues, including skin.
 

Combating Rising Medical Costs and the Baby Boomer Demographic

Beyond the obvious health benefits of regenerative medicine and adult stem cell therapy, this technology is desperately needed to combat rising healthcare costs. Current national healthcare costs are in excess of $1.5 trillion annually, or 13 percent of Gross Domestic Product (GDP). By 2040, as the last baby boomer becomes a senior citizen, the population of senior citizens over the age of 65 in the U.S. will be double today's number, for a total of 70 million. Accordingly, as much as 25 percent of the U.S. GDP would be devoted to healthcare by 2040. The majority of these projected costs stem from recurring treatments for diseases that arise from tissue failure commonly seen in the elderly.
 

The baby boomer demographic is one that has seen continual medical advancement in their lifetime. This group expects the best from healthcare and will have the greatest need for regenerative medicine. These therapies will help combat common diseases in the elderly such as diabetes, osteoporosis, and cardiovascular disease. Baby boomers will almost certainly rally behind the efforts to advance regenerative medicine as it offers them the greatest hope for the most effective medical treatment and quality of life in their senior years.

News Releases

• Healtheuniverse Develops Technology to Create Non-Embryonic Adult Stem Cells From Fat (Tue, Feb 14)

• Healtheuniverse Announces Appointment of Plastic and Reconstructive Surgeon Richard A. Levine, MD to Its Medical and Scientific Advisory Board (Wed, Feb 1)

• HEALTHeUNIVERSE Announces Establishment of Euphora Brand (Mon, Dec 19)
 

• HEALTHeUNIVERSE Announces CEO to Present New Class of Antibiotics for Use With Complicated Skin Structure Infections for Wyeth (Fri, Dec 16)

• Healtheuniverse Announces Organizational Structure to Optimize Division Strength and Operational Efficiencies (Mon, Dec 12)

• Healtheuniverse Announces Consulting Division Revenues Expected to Fund Research and Development of Adult Stem Cell and Regenerative Medicine Technologies (Thu, Dec 8)
 

• Healtheuniverse to Establish Research and Development Base for Its Regenerative Medicine and Stem Cell Applications in Biopolis, Singapore (Tue, Dec 6)
 

Dr. Vipul Dev
CEO, Chairman of the Board

Dr. Vipul Dev is a Plastic and Reconstructive Surgeon. He is a fully trained general surgeon and is fully fellowship trained from the distinguished, University of Texas (South Texas Medical Center). He has a clinical practice in Newport Beach. Dr. Dev has numerous publications in the field of surgery and the application of computers in medicine. He is currently pursuing research applications and the utilization of artificial intelligence in the realm of plastic, reconstructive and cosmetic surgery. He has consulted for numerous technologies and Internet based health care websites. He also has extensive experience with start-up companies where he has guided them from initial formation to eventual public offering. He maintains many high level medical contacts and has developed a tremendous network in both the medical and business field. He is on the speaker's bureau of several pharmaceutical and device companies and serves as the medical director of a medical management company and a regional wound care center.
 

Thomas Raack
COO, Board Member
 

Thomas Raack has over 10 years of financial, executive and strategic management experience with a diverse group of private and publicly-held companies specializing in the development of technology, medical product distribution, biotechnology, and e-commerce. Mr. Raack has a broad base of business consulting experience and has assisted in structuring and completing reverse mergers, acquisitions, debt and equity financing, reorganizations, as well as designing and implementing financial communications and investor relations campaigns. Mr. Raack has an extensive network of nationwide contacts in the financial community including national and regional NASD broker dealers, fund managers, research analysts, institutional money managers, and retail brokers. Prior to joining Healtheuniverse, Mr. Raack was managing partner at Alliance Capital Resources, Newport Beach, CA. While at Alliance, Mr. Raack consulted for a NASDAQ listed company handling domestic mergers and acquisitions, venture capital transactions, public offerings and other financings, joint ventures, strategic alliances and distribution agreements. Previous experience included Director of Investor Relations for a NASDAQ listed technology company while at Strategic Capital Consultants, Inc. a Los Angeles based corporate finance and financial consulting firm. Mr. Raack received a B.A. in Communications from California State University, Long Beach.
 

Sandip Shah
CIO, Board Member

Mr. Sandip Shah, President of Shah & Associates, has over 10 years of financial, corporate and investment banking experience and has been involved with various public and private companies including technology, communications, and medical companies such as Webbed, Healtheon, Clear Channel Communications and Surgerynet. Mr. Shah has assisted companies to grow from private companies to well-financed public traded household names through corporate finance, bridge loans, private placements, initial and secondary public offerings, market support and investor relations. Prior to establishing Shah & Associates, Mr. Shah was Vice President at Morgan Stanley Beverly Hills, as an integral member of the Investment Banking team. Mr. Shah received a B.S. in Artificial Intelligence/Computer Science from the University of California, San Diego.
 

Contacts

HEALTHeUNIVERSE
1171 W. San Bernardino Road, Suite F
Covina, California 91722
Tel:(800) 719-7424
FAX:(626) 967-4610
Investor relations: ir@healtheuniverse.com
 

This report includes forward-looking statements that reflect Healtheuniverse, Inc. current expectations about its future results, performance, prospects and opportunities. Healtheuniverse, Inc. has tried to identify these forward-looking statements by using words and phrases such as "may," "will," "expects," "anticipates," "believes," "intends," "estimates," "plan," "should," "typical," "preliminary," "we are confident" or similar expressions. These forward-looking statements are based on information currently available and are subject to a number of risks, uncertainties and other factors that could cause Healtheuniverse, Inc.'s actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. These risks, uncertainties and other factors include, without limitation, the Company's growth expectations and ongoing funding requirements, and specifically, the Company's growth prospects with scalable customers, and those outlined above. Other risks include the Company's limited operating history, the Company's history of operating losses, consumers' acceptance, the Company's use of licensed technologies, risk of increased competition, the potential need for additional financing, the terms and conditions of any financing that is consummated, the limited trading market for the Company's securities, the possible volatility of the Company's stock price, the concentration of ownership, and the potential fluctuation in the Company's operating results.

AllPennyStocks.com feature stock reports are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this report was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. For more information see our disclaimer section, a link of which can be found on our web site. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. This is an advertisement for Healtheuniverse, Inc. The purpose of this advertisement, like any advertising, is to provide coverage and awareness for the company. The information provided in this advertisement is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.

© 1999-2005 AllPennyStocks.com. All rights reserved. AllPennyStocks.com is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. AllPennyStocks.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), AllPennyStocks.com will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the AllPennyStocks.com web site. AllPennyStocks.com has been compensated twenty five thousand dollars, by a non-affiliated third-party, ShazamStocks Inc. for its efforts in presenting the HLUN profile on its web site and distributing it to its database of subscribers as well as other services. AllPennyStocks.com may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report. As of the profile date, no shares have been sold. Information presented on our web site and within our reports contain "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “expects’”, “will,” “anticipates,” “estimates, “believes,” or that by statements indicating certain actions “may,” “could,” or “might” occur.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.